Lisata Therapeutics Secures Vital Patent for Certepetide
Lisata Therapeutics Strengthens Patent Portfolio
Lisata Therapeutics, Inc. (NASDAQ: LSTA), a clinical-stage pharmaceutical company, has received a significant boost in its intellectual property assets with the issuance of a new composition of matter patent for its investigational drug, certepetide. This patent offers protection until the year 2040, with an option for further extensions, significantly enhancing the company’s market position against generic competition.
Importance of the New Patent
The United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 12,351,653, which encompasses the specific chemical structure of certepetide, along with its pharmacokinetic properties and manufacturing methods, specifically in relation to treating solid tumors. This type of patent is considered the highest form of intellectual property protection, allowing Lisata Therapeutics to prevent others from producing or distributing the drug. The receipt of this patent marks a pivotal moment for the company as it not only safeguards the innovative treatment but also opens up numerous opportunities for commercialization and partnership ventures.
CEO Statement on Patent Significance
David J. Mazzo, Ph.D., President and CEO, highlighted the importance of this achievement, noting that it significantly increases the company’s value and solidifies its exclusive rights, which play a critical role in shaping Lisata’s future commercialization strategies. "We see this patent as a critical milestone, delaying potential generic alternatives for the next two decades and securing a stronger negotiating stance for future collaborations," he stated.
Understanding Certepetide
Certepetide is an innovative cyclic peptide designed to enhance the delivery of anti-cancer therapies targeting solid tumors. Leveraging a distinctive uptake mechanism, it allows co-administered drugs to penetrate effectively, significantly increasing their therapeutic impact. This target-specific approach not only improves drug efficacy against tumors but also alters the tumor microenvironment, which can enhance susceptibility to immunotherapies. Extensive preclinical studies have indicated that certepetide boosts the delivery of several emerging cancer treatments, including RNA-based therapies.
Certepetide's Progress in Clinical Trials
Lisata is committed to advancing certepetide's development, and preliminary trials have already shown promising safety and tolerability profiles, especially in combination with standard chemotherapy for pancreatic cancer. The company believes that certepetide has the potential to evolve multiple treatment modalities for various solid tumors, innovative advancements that could reshape patient outcomes in oncology.
Lisata’s Future Prospects
Lisata Therapeutics continues to explore significant partnerships that can propel the development of certepetide and other therapeutic candidates. The company’s efforts aim not only to meet anticipated milestones in the drug development landscape but also to ensure sustainable growth and enhanced shareholder value over time. With adequate capital estimated to extend through 2026, Lisata is poised for promising advancements in its clinical trials and ongoing research.
Recognition and Designations
Certepetide’s promising profile has earned it multiple designations, including Fast Track status in the U.S. for expedited development, Orphan Drug Designation for both pancreatic cancer and glioma in the U.S. and the E.U., and recognition for pediatric conditions, further underscoring its potential impact in oncology treatments.
Contact Information
For inquiries regarding investments or media, Lisata Therapeutics has dedicated contacts available. Investors may reach John Menditto, Vice President of Investor Relations, at 908-842-0084 or via email at jmenditto@lisata.com. Media inquiries can be directed to Elizabeth Coleman at ICR Healthcare at 203-682-4783 or elizabeth.coleman@icrhealthcare.com.
Frequently Asked Questions
What is certepetide?
Certepetide is a cyclic peptide under investigation for enhancing the delivery of anti-cancer drugs to solid tumors.
What patent has Lisata Therapeutics secured for certepetide?
Lisata has secured a composition of matter patent, extending its protection for certepetide until 2040, with the possibility of extensions.
How does certepetide improve cancer treatment?
Certepetide utilizes a unique uptake mechanism that enables more effective targeting and penetration of tumor cells by co-administered cancer therapies.
What milestones does Lisata expect over the next few years?
Lisata anticipates significant advancements in its ongoing clinical trials and expects its current capital to fund operations into late 2026.
Who can I contact for more information about Lisata Therapeutics?
Interested parties can contact John Menditto for investor inquiries or Elizabeth Coleman for media inquiries via the provided email addresses.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.